NJ-KENVUE
25.6.2024 12:16:26 CEST | Business Wire | Press release
Kenvue Inc. (NYSE: KVUE) (“Kenvue” or the “Company”), the world’s largest pure-play consumer health company by revenue, today released its first-ever Healthy Lives Mission Report and shared how the Company advanced the well-being of both people and planet in 2023.
“We recognize that human health is inseparably linked to environmental health and our commitment to everyday care extends to the planet we call home,” said Thibaut Mongon, Chief Executive Officer. “As we established Kenvue as an independent company, we also recommitted to our Healthy Lives Mission, our Environmental, Social and Governance strategy, and positioned our portfolio of iconic brands and Kenvuers around the world to build lasting positive change.”
In 2023, the Company deployed its science, operations, team members and brands to advance its Healthy Lives Mission focused on nurturing healthy people, enriching a healthy planet and maintaining healthy practice.
“In the past year, we have made meaningful progress with our Healthy Lives Mission, reduced our greenhouse gas (GHG) emissions and virgin plastic footprint, advanced the sustainable sourcing of paper, and developed values-led policies and programs to positively impact individuals and communities,” said Pamela Gill-Alabaster, Global Head of ESG & Sustainability. “As a global leader in consumer health, we will continue to draw on our brands, resources and platforms to help shape a healthy future for both people and planet.”
Highlights from the inaugural report include:
Healthy People: Kenvue equipped the communities in which it operates with innovative products and actionable information to make healthier decisions.
- We start with our team and take actions every day to foster an inclusive, equitable and diverse workplace culture and to create a sense of belonging for all. We’re committed to strengthening representation at all management levels.1 At the end of 2023, our global workforce was approximately 50% male and 50% female, and 36% of our U.S. employees identified as racial or ethnic minorities.2
- Through diversity of backgrounds and perspectives, we collaborated on innovations and product experiences that reflect the needs of our global consumers, including the Neutrogena® Purescreen+™ Mineral UV Tint Face Liquid Sunscreen range in the U.S. designed to be inclusive of varying skin tones with four flexible shades and the Johnson’s® Blackinho Poderoso line in Brazil for children with curly hair.
Healthy Planet: Kenvue helped safeguard the earth’s health and resources while managing the impacts it created.
- Investments in energy efficiency and decarbonization projects have resulted in Scope 1 and 2 GHG3,4,5 reductions of 26% since 2020.
- We’ve increased our use of renewable electricity6 to 65% through 18 onsite solar-powered electricity systems and offsite renewable electricity6 procurement contracts.
- Using circular economy design principles, we increased our use of recyclable7 or refillable8 packaging9 to 71% of our portfolio and reduced the volume of virgin plastic10 in packaging9 by 21%.
- Of our total paper and wood fiber packaging,11 94% of the volume sources were certified12 or verified recycled13 paper and wood fiber.
Healthy Practice: Kenvue also continued to promote a culture of integrity, ethics and transparency to build trust and create meaningful, long-term value.
- We’re committed to optimizing the environmental performance14 of our products using scientific lifecycle design principles15 and tools such as our Sustainable Innovation Profiler (SIP), which aims to future-proof products by promoting the adoption of sustainable ingredients and packaging materials in our innovation process.
- We’re expanding access to product information through digital platforms and technologies like our Neutrogena® Glossary of Ingredients and Johnson’s® Baby digital transparency tool with the intention of empowering consumers to make the best choices for themselves and their loved ones.
To read the Kenvue Healthy Lives Mission 2023 Report, visit www.kenvue.com/hlm-report-2023.
About Kenvue
Kenvue is the world’s largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson’s®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we believe in the extraordinary power of everyday care and our teams work every day to put that power in consumers’ hands and earn a place in their hearts and homes. Learn more at www.kenvue.com.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding the Company’s climate goals and its Healthy Lives Mission. Forward-looking statements may be identified by the use of words such as “plans,” “expects,” “commits,” “will,” “anticipates,” “estimates” and other words of similar meaning. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kenvue and its affiliates.
A list and descriptions of risks, uncertainties and other factors can be found in Kenvue’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and subsequent Quarterly Reports on Form 10-Q and other filings, available at www.kenvue.com or on request from Kenvue. Kenvue and its affiliates undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or developments, or otherwise.
1 All management levels including manager, director, vice president and above.
2 Asian, Black/African American, Hispanic/Latino, Other Ethnic Racial Diversity; 2+ more races, NH/PI, AI/AN (Native Hawaiian or Pacific Islander, American Indian or Alaska Native). Workforce composition metrics are derived from data collected in connection with EEO-1 reporting.
3 Applies to all Kenvue-owned facilities where Kenvue has operational control, regardless of building type; all leased facilities used for manufacturing and/or research and development; and leased, non-manufacturing and/or non-research and development facilities where the facility is greater than 50,000 square feet and where Kenvue has operational control. The 2020 baseline and all subsequent reporting years include all facilities aligned to Kenvue’s structure upon separation from Johnson & Johnson in 2023 and do not include any operational or organizational exclusions. Scope 1 are greenhouse gas (GHG) emissions that Kenvue directly generates – e.g., running boilers and vehicles using fossil fuels. Fleet emissions are reported as CO2 and do not include other greenhouse gas emissions. Scope 2 are GHG emissions that Kenvue indirectly generates – from electricity or energy purchased for heating and cooling buildings.
4 The inventory was compiled in accordance with the WRI/WBCSD Greenhouse Gas (GHG) Protocol – A Corporate Accounting and Reporting Standard (Revised Edition 2013) including the amendment to this protocol, GHG Protocol Scope 2 Guidance (2015).
5 The target boundary includes land-related emissions and removals from bioenergy feedstocks.
6 Renewable energy source is an energy source that is capable of being replenished in a short time through ecological cycles or agricultural processes (e.g., biomass, geothermal, hydro, solar, wind). Renewable electricity targets are achieved through a combination of actions, including on-site solar, virtual power purchase agreements (VPPAs), direct power purchase agreements (PPAs), energy attribute certificates (EACs), also known as renewable electricity certificates (RECs), and green retail contracts.
7 Recyclable also defined as recycle-ready is when packaging is designed for collection, sorting, and recycling using end-of-life processes, but where collection, sorting, and recycling infrastructure may not yet be in place for the packaging to actually be recycled. Best practices of “designing for recyclability" guidance for plastic-based packaging include the Association of Plastics Recyclers in the United States. Note: "Designed for recycling," "designed for recyclability," and "recycle ready" are also used interchangeably and reflect the same meaning.
8 Kenvue defines refillable or reusable packaging as packaging that is designed for either the business or the consumer to put the same type of purchased product back into the original packaging, is designed to be returnable and/or refillable, and accomplishes a minimum number of reuses by being part of a system that enables reuse.
9 Packaging for direct purchases, may not include all externally manufactured products. Total weight of plastics packaging is calculated utilizing 2024 Business Plan volume and is not trued up to actual sales. Manual adjustments of <10% were made to 2024 Business Plan volume based on SME judgment to remove materials not assumed to contain plastics.
10 Virgin plastic means newly manufactured resin produced from petrochemical feedstock used as the raw material for the manufacture of plastic products and which has never been used or processed before.
11 Volumes include direct purchases of primary and secondary packaging and leaflets. Volumes do not include the packaging materials sourced in some externally manufactured products.
12 Certification schemes accepted by Kenvue include FSC® or PEFC chain of custody standard, only when FSC® is not available.
13 Recycled includes both post-consumer and post-industrial recycled content; Verification of recycled content is conducted by an external third party (for example, Preferred by Nature). The information provided herein includes data from suppliers. While we strive to ensure the accuracy and completeness of this data, we recognize there may be limitations to its accuracy or comprehensiveness.
14 Improved environmental performance is defined as improvement in one or more of the four pillars, with no regression compared to the baseline product, measured using Kenvue’s Sustainable Innovation Profiler (SIP).
15 Scientific principles are defined across four pillars – carbon footprint, green chemistry, sustainable packaging, and product environmental footprint.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240625119963/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
